Yuk-Ching Tse-Dinh

Prof. Yuk-Ching Tse-Dinh

Florida International University
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
KTKemin Tan
Kemin Tan
QZQingxuan Zhou
Qingxuan Zhou
BCBokun Cheng
Bokun Cheng
ZZZhongtao Zhang
Zhongtao Zhang
AJAndrzej Joachimiak
Andrzej Joachimiak
YTYuk-Ching Tse-Dinh
Yuk-Ching Tse-Dinh
Escherichia coli topoisomerase I has an essential function in preventing hypernegative supercoiling of DNA. A full length structure of E. coli topoisomerase I reported here shows how the C-terminal domains bind single-stranded DNA (ssDNA) to recognize the accumulation of negative supercoils in duplex DNA. These C-terminal domains of E. coli topoisomerase I are known to interact with RNA polymerase, and two flexible linkers within the C-terminal domains may assist in the movement of the ssDNA for the rapid removal of transcription driven negative supercoils. The structure has also unveiled for the first time how the 4-Cys zinc ribbon domain and zinc ribbon-like domain bind ssDNA with primarily π-stacking interactions. This novel structure, in combination with new biochemical data, provides important insights into the mechanism of genome regulation by type IA topoisomerases that is essential for life, as well as the structures of homologous type IA TOP3α and TOP3β from higher eukaryotes that also have multiple 4-Cys zinc ribbon domains required for their physiological functions.

1 March 2015 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
YTYuk-Ching Tse-Dinh
Yuk-Ching Tse-Dinh
Resistance of bacterial pathogens to current antibiotics has grown to be an urgent crisis. Approaches to overcome this challenge include identification of novel targets for discovery of new antibiotics. Bacterial topoisomerase I is present in all bacterial pathogens as a potential target for bactericidal topoisomerase poison inhibitors. Recent efforts have identified inhibitors of bacterial topoisomerase I with antibacterial activity. Additional research on the mode of action and binding site of these inhibitors would provide further validation of the target and establish that bacterial topoisomerase I is druggable. Bacterial topoisomerase I is a potentially high value target for discovery of new antibiotics. Demonstration of topoisomerase I as the cellular target of an antibacterial compound would provide proof-of-concept validation.

8 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BCBokun Cheng
Bokun Cheng
SCShugeng Cao
Shugeng Cao
VVVictor Vasquez
Victor Vasquez
TAThirunavukkarasu Annamalai
Thirunavukkarasu Annamalai
GTGiselle Tamayo-Castillo
Giselle Tamayo-Castillo
YTYuk-Ching Tse-Dinh
Yuk-Ching Tse-Dinh
Topoisomerase inhibitors are effective for antibacterial and anticancer therapy because they can lead to the accumulation of the intermediate DNA cleavage complex formed by the topoisomerase enzymes, which trigger cell death. Here we report the application of a novel enzyme-based high-throughput screening assay to identify natural product extracts that can lead to increased accumulation of the DNA cleavage complex formed by recombinant Yersinia pestis topoisomerase I as part of a larger effort to identify new antibacterial compounds. Further characterization and fractionation of the screening positives from the primary assay led to the discovery of a depside, anziaic acid, from the lichen Hypotrachyna sp. as an inhibitor for both Y. pestis and Escherichia coli topoisomerase I. In in vitro assays, anziaic acid exhibits antibacterial activity against Bacillus subtilis and a membrane permeable strain of E. coli. Anziaic acid was also found to act as an inhibitor of human topoisomerase II but had little effect on human topoisomerase I. This is the first report of a depside with activity as a topoisomerase poison inhibitor and demonstrates the potential of this class of natural products as a source for new antibacterial and anticancer compounds.

1 January 2016 in Journal of Molecular Biology
Verified
Journal Article
Closed access
KTKemin Tan
Kemin Tan
NCNan Cao
Nan Cao
BCBokun Cheng
Bokun Cheng
AJAndrzej Joachimiak
Andrzej Joachimiak
YTYuk-Ching Tse-Dinh
Yuk-Ching Tse-Dinh

10 June 2016 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
YTYuk-Ching Tse-Dinh
Yuk-Ching Tse-Dinh
DNA gyrase and topoisomerase IV are type IIA bacterial topoisomerases that are targeted by highly effective antibiotics. However, resistance via multiple mechanisms arises to limit the efficacies of these drugs. Continued research on type IIA bacterial topoisomerases has provided novel approaches to counter the most common resistance mechanism for utilization of these proven targets in antibacterial therapy. Bacterial topoisomerase I is being explored as an alternative target that is not expected to show cross-resistance. Dual targeting or combination therapy could be strategies for circumventing the development of resistance to topoisomerase-targeting antibiotics. Bacterial topoisomerases are high-value bactericidal targets that could continue to be exploited for antibacterial therapy, if new tactics to counter resistance can be adopted.

14 June 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
NCNan Cao
Nan Cao
KTKemin Tan
Kemin Tan
TAThirunavukkarasu Annamalai
Thirunavukkarasu Annamalai
AJAndrzej Joachimiak
Andrzej Joachimiak
YTYuk-Ching Tse-Dinh
Yuk-Ching Tse-Dinh
We have obtained new crystal structures of Mycobacterium tuberculosis topoisomerase I, including structures with ssDNA substrate bound to the active site, with and without Mg2+ ion present. Significant enzyme conformational changes upon DNA binding place the catalytic tyrosine in a pre-transition state position for cleavage of a specific phosphodiester linkage. Meanwhile, the enzyme/DNA complex with bound Mg2+ ion may represent the post-transition state for religation in the enzyme's multiple-step DNA relaxation catalytic cycle. The first observation of Mg2+ ion coordinated with the TOPRIM residues and DNA phosphate in a type IA topoisomerase active site allows assignment of likely catalytic role for the metal and draws a comparison to the proposed mechanism for type IIA topoisomerases. The critical function of a strictly conserved glutamic acid in the DNA cleavage step was assessed through site-directed mutagenesis. The functions assigned to the observed Mg2+ ion can account for the metal requirement for DNA rejoining but not DNA cleavage by type IA topoisomerases. This work provides new structural insights into a more stringent requirement for DNA rejoining versus cleavage in the catalytic cycle of this essential enzyme, and further establishes the potential for selective interference of DNA rejoining by this validated TB drug target.